Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir prophylaxis for CMV infection in severe aplastic anemia treated with intensive IST + TPO receptor agonist
ChiCTR2500106152Phase 4Recruiting
- Sponsor
- Suzhou Hongci Hematology Hospital
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of letermovir in aplastic anemia and cytomegalovirus disease (CMV) (2 arms), sponsored by Suzhou Hongci Hematology Hospital. Primary endpoint: Incidence of CMV infection within 14 weeks after treatment. Started Jul 2025; status: recruiting.
02
Drugs
letermovir
03
Conditions
aplastic anemiacytomegalovirus disease (CMV)
Beyond the preview
Go deeper on ChiCTR2500106152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106152.